Butterfly Pea Laboratory Co., Ltd. announced that it has received funding on October 2, 2023. The transaction included participation from new investors Rohto Pharmaceutical Co.,Ltd.,Symba Holdings Co., Ltd.,individual investors Yusuke Shimizu,private investors and others.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,036 JPY | +2.50% | +4.03% | +6.79% |
Apr. 04 | Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen | MT |
Apr. 04 | Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.79% | 4.4B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4527 Stock
- News Rohto Pharmaceutical Co.,Ltd.
- Butterfly Pea Laboratory Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd. and other investors.